Combination of <scp>PARP</scp> Inhibitor and Antiangiogenic Therapy Following Disease Progression in Patients With Epithelial Ovarian Cancer Undergoing <scp>PARP</scp> Inhibitor Maintenance Therapy: A Real‐World Study
Combining antiangiogenic therapy with the original PARPi may benefit patients with ascites-free ovarian cancer and a low tumour burden who experience disease progression following PARPi maintenance therapy.
Authors
- Hong Zheng
- Hongguo Wang
- Yunong Gao
- Nan Zhang (ORCID: https://orcid.org/0000-0001-7578-5648)
- Yan Cai (ORCID: https://orcid.org/0000-0001-9285-9012)
- Tong Shu (ORCID: https://orcid.org/0000-0001-5952-3090)
Institutions
- Peking University (CN)
- Peking University Cancer Hospital (CN)
Publication Details
- Journal
- BJOG An International Journal of Obstetrics & Gynaecology
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1111/1471-0528.18179
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 0.00